Prognostic markers and new, innovative treatments in renal cell carcinoma
C. Secasan. Saudi.J.Kidney Dis.Transpl., 20 (3):
355-361(2009)
Abstract
We reviewed the current medical literature to present the prognostic markers and current treatments of Renal Cell Carcinoma (RCC) and to propose new and innovative treatments for RCC. A PubMed search (http://www.ncbi.nlm.nih.gov/PubMed/) was performed and prognostic markers in RCC were reviewed and presented here. We hypothesize our own innovative theoretical research in new treatments for RCC. This includes a combination formed of an anticancer vaccine (VAX-x), which prevents the emergence of drug-resistance to (DRUG-x), with its corresponding anticancer drug (DRUG-x), administrated after immunological response to (VAX-x), can be employed to successfully treat and cure RCC in its various stages. We therefore propose that new treatment options of RCC are possibly VAX-x with either of the tyrosine kinase inhibitors-sunitinib or sorafenib
%0 Journal Article
%1 Secasan.2009
%A Secasan, C. C.
%D 2009
%J Saudi.J.Kidney Dis.Transpl.
%K Carcinoma Research Tyrosine response surgery
%N 3
%P 355-361
%T Prognostic markers and new, innovative treatments in renal cell carcinoma
%U PM:19414934
%V 20
%X We reviewed the current medical literature to present the prognostic markers and current treatments of Renal Cell Carcinoma (RCC) and to propose new and innovative treatments for RCC. A PubMed search (http://www.ncbi.nlm.nih.gov/PubMed/) was performed and prognostic markers in RCC were reviewed and presented here. We hypothesize our own innovative theoretical research in new treatments for RCC. This includes a combination formed of an anticancer vaccine (VAX-x), which prevents the emergence of drug-resistance to (DRUG-x), with its corresponding anticancer drug (DRUG-x), administrated after immunological response to (VAX-x), can be employed to successfully treat and cure RCC in its various stages. We therefore propose that new treatment options of RCC are possibly VAX-x with either of the tyrosine kinase inhibitors-sunitinib or sorafenib
@article{Secasan.2009,
abstract = {We reviewed the current medical literature to present the prognostic markers and current treatments of Renal Cell Carcinoma (RCC) and to propose new and innovative treatments for RCC. A PubMed search (http://www.ncbi.nlm.nih.gov/PubMed/) was performed and prognostic markers in RCC were reviewed and presented here. We hypothesize our own innovative theoretical research in new treatments for RCC. This includes a combination formed of an anticancer vaccine (VAX-x), which prevents the emergence of drug-resistance to (DRUG-x), with its corresponding anticancer drug (DRUG-x), administrated after immunological response to (VAX-x), can be employed to successfully treat and cure RCC in its various stages. We therefore propose that new treatment options of RCC are possibly VAX-x with either of the tyrosine kinase inhibitors-sunitinib or sorafenib},
added-at = {2010-02-05T11:28:39.000+0100},
author = {Secasan, C. C.},
biburl = {https://www.bibsonomy.org/bibtex/230e84680564f53b5a55a808de6c0f902/kanefendt},
interhash = {1d1d256a284da87a0c902c8602962960},
intrahash = {30e84680564f53b5a55a808de6c0f902},
journal = {Saudi.J.Kidney Dis.Transpl.},
keywords = {Carcinoma Research Tyrosine response surgery},
number = 3,
pages = {355-361},
timestamp = {2010-02-05T11:28:53.000+0100},
title = {Prognostic markers and new, innovative treatments in renal cell carcinoma},
url = {PM:19414934},
volume = 20,
year = 2009
}